Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Up-Front Randomization 10 Years Later: The AML Cooperative Group Strategy

Thomas Buchner, MD, Wolfgang E. Berdel, MD, Bernhard J. Woermann, MD, Maria Cristina Sauerland, MSc, Achim Heinecke, PhD, Utz Krug, MD, Wolfgang Hiddemann, MD

Blood (2014) 124 (21): 2267.

https://doi.org/10.1182/blood.V124.21.2267.2267

Published: 2014

Journal Articles

A Combined Molecular and Clinical Prognostic Index For Relapse and Survival In Cytogenetically Normal AML (PINA)

Blood (2013) 122 (21): 1303.

https://doi.org/10.1182/blood.V122.21.1303.1303

Published: 2013

Journal Articles

Acute Myeloid Leukemia: The Outcome Is Determined By Age, Genetic Group, White Blood Cell Count, Lactate Dehydrogenase, Rather Than By Chemotherapy Intensity

Blood (2013) 122 (21): 1447.

https://doi.org/10.1182/blood.V122.21.1447.1447

Published: 2013

Journal Articles

Acute Myeloid Leukemia: Longterm Outcome Predicted by Age and Genetic Groups

Thomas Buchner, MD, Wolfgang E. Berdel, MD, Utz Krug, Claudia Haferlach, MD, Susanne Schnittger, PhD, Matthias Stelljes, MD, Gerda Silling, MD, Peter Staib, MD, Andreas Grueneisen, MD, Albrecht Reichle, Leopold Balleisen, MD, Hartmut Eimermacher, MD, Aristoteles Giagounidis, MD, Herbert Rasche, MD, Eva Lengfelder, MD, Cristina Sauerland, MSc, Achim Heinecke, PhD, Bernhard Josef Woermann, MD, Wolfgang Hiddemann, MD, PhD

Blood (2012) 120 (21): 1509.

https://doi.org/10.1182/blood.V120.21.1509.1509

Published: 2012

Journal Articles

Allogeneic Stem Cell Transplantation Versus Conventional Postremission Therapy for Acute Myeloid Leukemia in First Complete Remission: A Matched Pairs Analysis

Blood (2012) 120 (21): 1974.

https://doi.org/10.1182/blood.V120.21.1974.1974

Published: 2012

Journal Articles

Loss of Structural Maintenance of Chromosomes 1A Protein Expression Is Associated with a Poor Prognosis in Acute Myelogenous Leukemia.

Utz O. Krug, MD, Claudia Hömme, PhD, Nicola Tidow, PhD, Horst Buerger, MD, Gabriele Koehler, MD, Achim Heinecke, PhD, Thomas Buchner, MD, Wolfgang E Berdel, MD, Steffen Koschmieder, MD, Carsten Mueller-Tidow, MD

Blood (2009) 114 (22): 4693.

https://doi.org/10.1182/blood.V114.22.4693.4693

Published: 2009

Journal Articles

A Novel Risk Score Predicts the Likelihood of a Complete Remission After Intensive Induction Therapy in Older AML Patients.

Utz O. Krug, MD, Achim Heinecke, PhD, Anja Koschmieder, MD, Matthias Stelljes, MD, Maria Cristina Sauerland, PhD, Wolfgang E Berdel, MD, Bernhard J Woermann, MD, Wolfgang Hiddemann, MD, Thomas Buchner, MD, Carsten Müller-Tidow, MD

Blood (2009) 114 (22): 327.

https://doi.org/10.1182/blood.V114.22.327.327

Published: 2009

Journal Articles

Prolonged Monthly Myelosuppressive Maintenance Chemotherapy in Acute Myeloid Leukemia: The AMLCG Experience.

Utz O. Krug, MD, Wolfgang E. Berdel, MD, Maria Cristina Sauerland, Achim Heinecke, PhD, Bernhard Josef Wormann, MD, Wolfgang Hiddemann, MD, Thomas Buchner, MD

Blood (2007) 110 (11): 1856.

https://doi.org/10.1182/blood.V110.11.1856.1856

Published: 2007

Journal Articles

Prognostic Impact of Clinical and Molecular Markers in Normal Karyotype AML-Results from the AMLCG 2000 Trial.

Friederike Schneider, Eva Hoster, PhD, Marietta Rottenkolber, PhD, Stephanie Schneider, PhD, Annika Dufour, PhD, Tobias Benthaus, Gudrun Mellert, Evelyn Zellmeier, Stefan K. Bohlander, MD, Michael Unterhalt, MD, Michaela Feuring-Buske, MD, Christian Buske, MD, Jan Braess, MD, Achim Heinecke, PhD, Wolfgang E. Berdel, MD, Thomas Buechner, MD, Wolfgang Hiddemann, MD, Karsten Spiekermann, MD

Blood (2007) 110 (11): 3482.

https://doi.org/10.1182/blood.V110.11.3482.3482

Published: 2007

Journal Articles

FLT3-ITD but Not FLT3-TKD Mutations Have Major Prognostic Impact in Normal Karyotype AML.

Stephanie Schneider, PhD, Friederike Schneider, Annika Dufour, PhD, Gudrun Mellert, Evelyn Zellmeier, Jan Braess, MD, Stefan K. Bohlander, MD, Michaela Feuring-Buske, MD, Christian Buske, MD, Susanne Fritsch, Achim Heinecke, PhD, Maria C. Sauerland, PhD, Eva Hoster, PhD, Michael Unterhalt, MD, Wolfgang E. Berdel, MD, Bernhard J. Wormann, MD, Thomas Buechner, MD, Wolfgang Hiddemann, MD, Karsten Spiekermann, MD

Blood (2007) 110 (11): 3486.

https://doi.org/10.1182/blood.V110.11.3486.3486

Published: 2007

Journal Articles

Changes in the Hierarchy of Risk Factors with Older Age in De-Novo Acute Myeloid Leukemia (AML).

Thomas Buchner, MD, Wolfgang E. Berdel, MD, Claudia Schoch, MD, Torsten Haferlach, MD, Hubert L. Serve, MD, Joachim Kienast, MD, Susanne Schnittger, PhD, Wolfgang Kern, MD, Joelle Tchinda, MD, Albrecht Reichle, MD, Peter Staib, MD, Wolf-Dieter Ludwig, MD, Carlo Aul, MD, Maria Cristina Sauerland, Dipl Math, Achim Heinecke, PhD, Bernhard Josef Wormann, MD, Wolfgang Hiddemann, MD

Blood (2006) 108 (11): 1977.

https://doi.org/10.1182/blood.V108.11.1977.1977

Published: 2006

Journal Articles

Intensification of Induction by High-Dose AraC and Outcome in Older Patients with De-Novo Acute Myeloid Leukemia (AML) and Subsets.

Thomas Buchner, MD, Wolfgang E. Berdel, MD, Claudia Schoch, MD, Torsten Haferlach, MD, Joelle Tchinda, MD, Susanne Schnittger, PhD, Wolfgang Kern, MD, Albrecht Reichle, MD, Peter Staib, MD, Hubert L. Serve, MD, Wolf-Dieter Ludwig, MD, Maria Cristina Sauerland, Dipl Math, Achim Heinecke, PhD, Bernhard Josef Wormann, MD, Wolfgang Hiddemann, MD

Blood (2006) 108 (11): 1978.

https://doi.org/10.1182/blood.V108.11.1978.1978

Published: 2006

Journal Articles

NPM-1, but Not FLT3-ITD Mutations Predict Early Blast Cell Clearance and CR Rate in Patients with Normal Karyotype AML or High-Risk Myelodysplastic Syndrome (MDS).

Karsten Spiekermann, MD, Annika Dufour, PhD, Gudrun Mellert, Evelin Zellmeier, Jan Braess, MD, Stefan K. Bohlander, MD, Michaela Feuring-Buske, MD, Christian Buske, MD, Susanne Fritsch, MD, Achim Heinecke, PhD, Maria C. Sauerland, PhD, Eva Hoster, PhD, Michael Unterhalt, MD, Wolfgang E. Berdel, MD, Bernhard Josef Wormann, MD, Thomas Buchner, MD, Wolfgang Hiddemann, MD, Acute Myeloid Leukemia Cooperative Group (AMLCG)

Blood (2006) 108 (11): 805.

https://doi.org/10.1182/blood.V108.11.805.805

Published: 2006

Journal Articles

Conditioning with 8 Gy Total Body Irradiation and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: Projected 4-Year Update.

Matthias Stelljes, MD, Martin Bornhaeuser, MD, Matthias Kroger, MD, Joerg Beyer, MD, Maria C. Sauerland, Achim Heinecke, PhD, Bjorna Berning, MD, Christian Scheffold, MD, Gerda Silling, MD, Thomas Buchner, MD, Andreas Neubauer, MD, Axel Arthur Fauser, MD, Gerhard Ehninger, MD, Wolfgang E. Berdel, MD, Joachim Kienast, MD

Blood (2006) 108 (11): 3016.

https://doi.org/10.1182/blood.V108.11.3016.3016

Published: 2006

Journal Articles

Prospective Multicenter Study for Patients with Therapy - Related Acute Myeloid Leukemia (AML) Using Intensive Induction and Postremission Therapy.

Bernhard Josef Wormann, MD, Claudia Schoch, MD, Albrecht Reichle, MD, Peter Staib, MD, Wolf-Dieter Ludwig, MD, Maria Cristina Sauerland, Achim Heinecke, PhD, Wolfgang E. Berdel, MD, Wolfgang Hiddemann, MD, Thomas Buchner, MD

Blood (2006) 108 (11): 2001.

https://doi.org/10.1182/blood.V108.11.2001.2001

Published: 2006

Journal Articles

Double Induction Containing Two Courses Versus One Course of High- Dose AraC/ Mitoxantrone (HAM) and Autologous Stem Cell Transplantation Versus Prolonged Maintenance for Acute Myeloid Leukemia (AML).

Thomas Buchner, MD, Wolfgang E. Berdel, MD, Claudia Schoch, MD, Torsten Haferlach, MD, Hubert L. Serve, MD, Joachim Kienast, MD, Susanne Schnittger, PhD, Wolfgang Kern, MD, Joelle Tchinda, PhD, Albrecht Reichle, MD, Peter Staib, MD, Wolf-Dieter Ludwig, MD, Carlo Aul, MD, Maria-Cristina Sauerland, Achim Heinecke, PhD, Bernhard Woermann, MD, Wolfgang Hiddemann, MD

Blood (2005) 106 (11): 272.

https://doi.org/10.1182/blood.V106.11.272.272

Published: 2005

NARROW

Up-Front Randomization 10 Years Later: The AML Cooperative Group Strategy

A Combined Molecular and Clinical Prognostic Index For Relapse and Survival In Cytogenetically Normal AML (PINA)

Acute Myeloid Leukemia: The Outcome Is Determined By Age, Genetic Group, White Blood Cell Count, Lactate Dehydrogenase, Rather Than By Chemotherapy Intensity

Acute Myeloid Leukemia: Longterm Outcome Predicted by Age and Genetic Groups

Allogeneic Stem Cell Transplantation Versus Conventional Postremission Therapy for Acute Myeloid Leukemia in First Complete Remission: A Matched Pairs Analysis

Loss of Structural Maintenance of Chromosomes 1A Protein Expression Is Associated with a Poor Prognosis in Acute Myelogenous Leukemia.

A Novel Risk Score Predicts the Likelihood of a Complete Remission After Intensive Induction Therapy in Older AML Patients.

Prolonged Monthly Myelosuppressive Maintenance Chemotherapy in Acute Myeloid Leukemia: The AMLCG Experience.

Prognostic Impact of Clinical and Molecular Markers in Normal Karyotype AML-Results from the AMLCG 2000 Trial.

FLT3-ITD but Not FLT3-TKD Mutations Have Major Prognostic Impact in Normal Karyotype AML.

Changes in the Hierarchy of Risk Factors with Older Age in De-Novo Acute Myeloid Leukemia (AML).

Intensification of Induction by High-Dose AraC and Outcome in Older Patients with De-Novo Acute Myeloid Leukemia (AML) and Subsets.

NPM-1, but Not FLT3-ITD Mutations Predict Early Blast Cell Clearance and CR Rate in Patients with Normal Karyotype AML or High-Risk Myelodysplastic Syndrome (MDS).

Conditioning with 8 Gy Total Body Irradiation and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: Projected 4-Year Update.

Prospective Multicenter Study for Patients with Therapy - Related Acute Myeloid Leukemia (AML) Using Intensive Induction and Postremission Therapy.

Double Induction Containing Two Courses Versus One Course of High- Dose AraC/ Mitoxantrone (HAM) and Autologous Stem Cell Transplantation Versus Prolonged Maintenance for Acute Myeloid Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only